+357 96 030922
info@marketpublishers.com

Lung Cancer Genomic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Products v/s Services), By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others), By Panel Type (Single Panel v/s Multi-Gene Panel), By Sample Type (Tissue Biopsy v/s Liquid Biopsy), By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others), By Region & Competition, 2021-2031F

https://marketpublishers.com/r/LE33B9433508EN.html
Date: January 2026
Pages: 183
Price: US$ 4,500.00 (Single User License)
ID: LE33B9433508EN

Abstracts

The Global Lung Cancer Genomic Testing Market will grow from USD 2.17 Billion in 2025 to USD 3.76 Billion by 2031 at a 9.59% CAGR. Lung cancer genomic testing involves the molecular analysis of tumor tissue or liquid biopsies to identify specific genetic alterations such as EGFR mutations or ALK rearrangements that dictate the selection of targeted therapies. The market is primarily propelled by the clinical transition toward personalized medicine and the stringent regulatory requirement for companion diagnostics to authorize the use of novel oncology drugs.

Key Market Drivers

The Rising Global Incidence and Prevalence of Lung Cancer serves as the foundational

+357 96 030922
info@marketpublishers.com

catalyst for the genomic testing market, creating an expanding patient pool that necessitates precise molecular diagnosis. As the burden of lung malignancy remains high globally, healthcare systems are increasingly mandating comprehensive biomarker testing for all newly diagnosed patients to determine the most effective management strategies. This volume-driven demand is evidenced by the sheer scale of diagnoses in major markets.

Key Market Challenges

The inconsistent reimbursement landscape for next-generation sequencing constitutes a substantial barrier hampering the growth of the Global Lung Cancer Genomic Testing Market. While clinical guidelines increasingly recommend comprehensive profiling, the lack of uniform payer coverage creates severe economic friction that disconnects clinical availability from patient accessibility. Diagnostic developers face restricted revenue potential as healthcare providers often hesitate to order advanced genomic profiling due to uncertainty regarding payment authorization.

Key Market Trends

The transition from single-gene assays to comprehensive next-generation sequencing (NGS) panels is reshaping the diagnostic standard for lung malignancy, driven by the need to efficiently identify multiple actionable alterations from limited tissue samples. Clinicians are increasingly abandoning iterative single-biomarker testing, which risks tissue exhaustion, in favor of broad genomic profiling that captures co-occurring mutations and complex signatures like tumor mutational burden in a single workflow. This consolidation is critical for matching patients to the growing array of targeted therapies without the latency of sequential testing.

Key Market Players

QIAGEN NV

Agilent Technologies Inc.

Thermo Fisher Scientific Inc.

Quest Diagnostics Incorporated

Laboratory Corporation of America Holdings

+357 96 030922
info@marketpublishers.com

CENTOGENE N.V.

BGI Genomics Co. Ltd.

CeGaT GmbH

Illumina Inc.

F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Market, By Component:

Products v/s Services

Lung Cancer Genomic Testing Market, By Technology:

Next Generation Sequencing

Polymerase Chain Reactions

Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)

Others

Lung Cancer Genomic Testing Market, By Panel Type:

Single Panel v/s Multi-Gene Panel

Lung Cancer Genomic Testing Market, By Sample Type:

Tissue Biopsy v/s Liquid Biopsy

+357 96 030922
info@marketpublishers.com

Lung Cancer Genomic Testing Market, By End User:

- Academic & Research Institutions
- Hospitals & Clinics
- Diagnostic Laboratories
- Others

Lung Cancer Genomic Testing Market, By Region:

- North America
  - United States
  - Canada
  - Mexico
- Europe
  - France
  - United Kingdom
  - Italy
  - Germany
  - Spain
- Asia Pacific
  - China
  - India

+357 96 030922
info@marketpublishers.com

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Genomic Testing Market.

Available Customizations:

Global Lung Cancer Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

+357 96 030922
info@marketpublishers.com

Contents

+357 96 030922
info@marketpublishers.com

6. NORTH AMERICA LUNG CANCER GENOMIC TESTING MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

7. EUROPE LUNG CANCER GENOMIC TESTING MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

8. ASIA PACIFIC LUNG CANCER GENOMIC TESTING MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

9. MIDDLE EAST & AFRICA LUNG CANCER GENOMIC TESTING MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

10. SOUTH AMERICA LUNG CANCER GENOMIC TESTING MARKET OUTLOOK

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Lung Cancer Genomic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component (Products v/s Services), By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others), By Panel Type (Single Panel v/s Multi-Gene Panel), By Sample Type (Tissue Biopsy v/s Liquid Biopsy), By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others), By Region & Competition, 2021-2031F

Product link: https://marketpublishers.com/r/LE33B9433508EN.html

Price: US$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/LE33B9433508EN.html